Drug Design, Development and Therapy (Jun 2013)

Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration

  • Tranos P,
  • Vakalis A,
  • Asteriadis S,
  • Koukoula S,
  • Vachtsevanos A,
  • Perganta G,
  • Georgalas I

Journal volume & issue
Vol. 2013, no. default
pp. 485 – 490

Abstract

Read online

Paris Tranos,1 Athanasios Vacalis,1 Solon Asteriadis,1 Stavrenia Koukoula,1 Athanasios Vachtsevanos,1 Georgia Perganta,1 Ilias Georgalas21Retina Centre, Thessaloniki, Greece; 2Department of Ophthalmology, "G Gennimatas" Hospital of Athens, University of Athens, Athens, GreeceAbstract: Age-related macular degeneration (AMD) is the main cause of visual impairment and blindness in people aged over 65 years in developed countries. Vascular endothelial growth factor (VEGF) is a positive regulator of angiogenesis and its proven role in the pathological neovascularization in wet AMD has provided evidence for the use of anti-VEGF agents as potential therapies. In this study, we review the literature for the possible causes of failure after treatment with anti-VEGF agents and attempt to propose an algorithm of suggestive actions to increase the chances of successful management of such difficult cases.Keywords: antiVEGF, age related macular degeneration, treatment